Taiwan's JHL Biotech raises $35m to develop biosimilars
This article was originally published in Scrip
Executive Summary
JHL Biotech, a Taiwanese company run by former Genentech executives, has raised $35m in a series B financing round, which it intends to use to develop its biosimilar monoclonal antibody pipeline.